Inflation Trends and Interest Rates: As a clinical-stage biotech company with limited revenue and reliance on financing, Allarity Therapeutics is highly sensitive to interest rate changes. Sustained inflation could lead to tighter monetary policy by the Federal Reserve (as indicated by FOMC Minutes and US CPI data), increasing the cost of capital and potentially making it more challenging for ALLR to secure future funding for its costly R&D and clinical trials, thus impacting its ability to bring drugs to market.

Biotech Sector Sentiment and Investment Flow: The broader sentiment towards the biotechnology sector, often influenced by overall economic outlook and investor risk appetite, significantly affects ALLR. Economic uncertainty or a shift away from high-growth, pre-revenue companies can reduce investor willingness to fund biotech ventures. Positive clinical trial results and regulatory milestones, such as FDA Fast Track designation for stenoparib, can attract investment, but a generally cautious market environment can still pose headwinds for fundraising.

Healthcare Policy and Regulatory Environment: The regulatory landscape for drug development, including FDA approval processes and funding for research (e.g., the VA's initiatives funding ALLR's SCLC trial), is a crucial macro factor. While positive regulatory actions like Fast Track designation expedite development, any broader shifts in healthcare policy regarding drug pricing, reimbursement, or clinical trial requirements could significantly impact the commercial viability and market access for Allarity's future drugs.